TRDA实时信号 | 通过Getagraph.com最大化利润

购买 118886 min ago

@ $14.49

发出时间: 13 Feb 2024 @ 22:30

回报率: -9.18%

上一信号: Feb 7 - 22:30

上一信号: 出售

回报率: 1.26 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases...

Stats
今日成交量	38 162.00
平均成交量	79 571.00
市值	442.19M
EPS	$0 ( 2024-03-18 )
下一个收益日期	( $-0.380 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-65.80
ATR14	$0.0680 (0.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Kim Peter S	Buy	2 600	Common Stock
2024-03-28	Kim Peter S	Buy	1 512	Common Stock
2024-03-26	Kim Peter S	Buy	2 750	Common Stock
2024-03-25	Kim Peter S	Buy	3 180	Common Stock
2024-03-22	Kim Peter S	Buy	3 118	Common Stock

INSIDER POWER
70.20
Last 99 transactions
Buy: 995 092 \| Sell: 209 386

音量相关性

長: 0.27 (neutral)

短: -0.04 (neutral)

Signal:(53.214) Neutral

Entrada Therapeutics, 相关性

10 最正相关
GXGX	0.876
MTP	0.872
HOL	0.871
PEV	0.864
IMGN	0.861
EPSN	0.85
PLIN	0.847
THCB	0.842
LGMK	0.839
CBIO	0.839

10 最负相关
RAVN	-0.874
CSPI	-0.853
NECB	-0.85
CREC	-0.848
TBSAU	-0.848
GHIX	-0.846
HOFT	-0.842
ENTF	-0.842
FICV	-0.842
IVAC	-0.839

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Entrada Therapeutics, 相关性 - 货币/商品

0.71
( moderate )

0.24
( neutral )

0.00
( neutral )

-0.01
( neutral )

-0.63
( weak negative )

Entrada Therapeutics, 财务报表

Annual	2023
营收:	$129.01M
毛利润:	$126.17M (97.80 %)
EPS:	$-0.200

FY	2023
营收:	$129.01M
毛利润:	$126.17M (97.80 %)
EPS:	$-0.200

FY	2022
营收:	$0
毛利润:	$-1.90M (0.00 %)
EPS:	$-2.79

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.97

Financial Reports:

No articles found.

Entrada Therapeutics,

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

实时更新： Entrada Therapeutics, [TRDA]

Upcoming Earnings Alert